HCPCS code J7322: Hymovis billing, units, and Medicare coverage

Key Takeaways

HCPCS code J7322 describes Hymovis (hyaluronan or derivative) for intra-articular injection, billed per 1 mg under Medicare Part B.

Each 8 mg/4 mL Hymovis vial yields 8 billing units; a full 2-injection treatment course totals 16 units billed across two dates of service.

Medicare coverage requires a confirmed osteoarthritis of the knee diagnosis and documented failure of conservative therapy per LCD A52420/A56157.

Pabau tracks injectable drug inventory, auto-populates J-codes, and streamlines CMS-1500 claim submission for in-office buy-and-bill programs.

Most denials on viscosupplementation claims trace back to two problems: wrong unit count and missing conservative-therapy documentation. HCPCS code J7322 covers Hymovis at 1 mg per billing unit, so an 8 mg vial generates 8 units per injection date. Get the unit count wrong and the claim underpays or triggers a payer audit. Skip the conservative-therapy note and Medicare rejects coverage outright. This guide covers the official HCPCS code J7322 description, Medicare coverage criteria, ASP-based reimbursement rates, buy-and-bill workflow, and the companion CPT codes you need on every claim.

HCPCS code J7322: official description and code details

HCPCS code J7322 is a medical billing Level II code maintained by the Centers for Medicare and Medicaid Services (CMS). It describes a single drug unit within the broader J-code category for drugs and biologicals administered in a clinical setting.

J7322 falls under the AAPC HCPCS Level II J-code series alongside related hyaluronan codes (J7320 through J7325). The code is assigned specifically to Hymovis and is not interchangeable with codes for other hyaluronic acid brands.

About Hymovis: the drug behind J7322

Hymovis is a hyaluronan-based viscosupplement manufactured by Fidia Pharma. It is indicated for the treatment of osteoarthritis of the knee in patients who have not responded to conservative non-pharmacologic therapy and simple analgesics.

• Formulation: 8 mg hyaluronan per 4 mL vial (2 mg/mL concentration)
• Treatment course: 2 intra-articular injections administered one week apart
• Mechanism: Viscosupplementation restores the viscoelastic properties of synovial fluid, reducing pain and improving joint mobility in knee osteoarthritis
• Administration setting: Physician office or outpatient facility; buy-and-bill model applies
• Why a J-code: Physician-administered drugs dispensed during an office visit are billed under HCPCS Level II J-codes rather than through a pharmacy benefit

Because J7322 is billed per 1 mg and each vial contains 8 mg, a single injection generates 8 billing units. A complete 2-injection course totals 16 units across two separate claim lines or two dates of service.

J7322 billing units and dosage

Unit miscalculation is the most common billing error on J7322 claims. The code is structured per 1 mg, so billers must convert the administered dose in milligrams directly to the number of units reported on the claim.

NDC reporting on Medicare Part B drug claims is required by CMS for separately payable drugs. Verify current CMS transmittals with your Medicare Administrative Contractor (MAC) to confirm NDC field requirements for your jurisdiction, as guidance can be updated through Change Requests.

J7322 Medicare coverage criteria

Medicare covers J7322 for musculoskeletal practice workflows treating knee osteoarthritis, but coverage is conditional. Two Local Coverage Determinations govern eligibility: LCD A52420 and LCD A56157, depending on the MAC jurisdiction. Both share the same core criteria.

• Confirmed diagnosis: Osteoarthritis of the knee, documented in the medical record with applicable ICD-10-CM diagnosis code (M17 series)
• Conservative therapy failure: The patient must have tried and failed appropriate conservative, non-pharmacologic therapy and/or simple analgesics before viscosupplementation is considered medically necessary
• Documentation of failure: The medical record must show the specific conservative treatments attempted, the duration of treatment, and the patient’s inadequate response
• Frequency limits: Medicare generally covers one course of treatment per knee per year (per the applicable LCD); do not assume unlimited repeat injections without verifying the current LCD frequency limitation in your MAC jurisdiction
• Bilateral knee: Coverage may apply to both knees if each meets the criteria independently, billed with appropriate ICD-10 laterality codes

ICD-10 diagnosis codes to pair with J7322

Every J7322 claim must carry a covered ICD-10 diagnosis code. The M17 series covers primary and other osteoarthritis of the knee. Use the most specific laterality available.

Always verify covered diagnosis codes against the current LCD in effect for your MAC. The list above reflects commonly accepted codes; individual LCD versions may specify inclusions or exclusions that differ by jurisdiction. Use insurance eligibility verification processes before administering the injection to confirm active coverage for the specific beneficiary.

J7322 reimbursement rate and fee schedule

Medicare reimburses J7322 under the revenue cycle management framework for Part B physician-administered drugs, using the Average Sales Price (ASP) plus 6% statutory add-on. ASP-based rates are updated quarterly by CMS.

Because ASP changes every quarter, always pull the current CMS ASP payment file before setting your charge master or estimating reimbursement for a treatment cycle. Rates cited in older billing guides may already be out of date.

Companion CPT code for injection administration

J7322 covers only the drug. The injection procedure itself requires a separate companion procedure code billed on the same claim. For knee joint injections, two CPT codes are commonly applicable.

Verify CPT code selection and applicable modifiers with your payer before billing. Place of service codes also affect reimbursement: POS 11 (office) and POS 22 (outpatient hospital) are both applicable depending on the setting; confirm with your MAC that the claimed POS matches where the service was actually performed.

Verify 20610 vs. 20611 selection with current AMA CPT codebook guidance and payer policies. Some commercial payers and Medicare Advantage plans may have additional documentation requirements for ultrasound-guided injections.

Streamline your in-office drug billing with Pabau

Pabau tracks injectable inventory, auto-populates HCPCS J-codes, and prepares CMS-1500 claims for buy-and-bill programs. See how practices billing viscosupplementation use Pabau to reduce claim errors and speed up reimbursement.

Book a demo

Buy and bill process for HCPCS code J7322 (Hymovis)

Hymovis is acquired and billed under the physician buy-and-bill model. The practice purchases the drug, administers it, and then bills the payer for both the drug and the administration service. Getting the workflow right at each step prevents denials and protects cash flow. A structured superbill that captures all required fields before the claim is submitted is the single most effective safeguard.

1. Acquire: Order Hymovis from an authorized wholesaler or distributor. Verify the NDC number on receipt and record the lot number and expiration date for your drug log.
2. Store: Store per Hymovis labeling requirements (typically refrigerated at 2-8 degrees C, protected from freezing). Maintain a temperature log.
3. Verify coverage before administering: Confirm the patient has active Medicare or commercial coverage, that the knee OA diagnosis is documented, and that conservative therapy failure is on record. For commercial plans, check whether prior authorization is required before the first injection.
4. Administer: Administer the intra-articular injection and document the administration note with date, dose, lot number, expiration date, and provider attestation.
5. Complete the claim: Bill J7322 with 8 units, the 11-digit NDC, CPT 20610 or 20611, the applicable ICD-10-CM M17 code, and the correct place of service. Submit on CMS-1500 (office) or UB-04 (outpatient hospital).
6. Reconcile: Match the remittance advice against expected ASP+6% reimbursement. Underpayment or denial requires review of the explanation of benefits for applicable remark codes before resubmitting.

Prior authorization requirements

Medicare Fee-for-Service generally does not require prior authorization for J7322 under traditional Medicare. However, Medicare Advantage (Part C) plans operate under their own PA rules. Most commercial payers require PA for viscosupplementation. Key documentation for a PA request includes:

• Confirmed OA knee diagnosis with applicable ICD-10 code
• Documented conservative therapy attempts and duration (physical therapy, analgesics, weight management)
• Physician attestation that conservative therapy failed to provide adequate relief
• Radiographic evidence of knee OA (X-ray or MRI report) where required by the payer

Documentation requirements for J7322 claims

Inadequate documentation is the leading cause of post-payment audits on viscosupplementation claims. Medical billing compliance for J7322 requires the medical record to support every coverage criterion from the applicable LCD. The goal is submitting a clean claim the first time, without a request for records.

• Diagnosis documentation: A physician note or consultation confirming osteoarthritis of the knee, with the ICD-10-CM code clearly linked to the injection order
• Conservative therapy record: Dates and types of prior treatments (NSAID use, physical therapy referrals, cortisone injections), with duration and outcome documented
• Injection administration note: Date of service, provider name, drug name (Hymovis), dose administered (8 mg), lot number, expiration date, site of injection (right/left/bilateral knee)
• NDC on the claim: The 11-digit NDC must appear in Box 24D of the CMS-1500 (with NDC qualifier N4 and units in the appropriate field per your MAC instructions)
• Ordering provider information: NPI of the administering and, where applicable, ordering physician

Retain all documentation for the standard Medicare audit retention period (currently 7 years). Payers conducting post-payment audits typically request the complete medical record, not just the claim face sheet.

Related HCPCS codes for hyaluronan products

J7322 is one of several HCPCS codes covering viscosupplementation products that frequently generate denial management questions when billed together or confused with each other. Each code is product-specific and not interchangeable. The table below covers the full J7320-J7325 series.

Never substitute J7321 for J7322 or vice versa based on perceived similarity. Each code is tied to a specific drug formulation. Billing J7321 when Hymovis was administered constitutes a coding error regardless of clinical similarity. Always bill the code that matches the drug actually dispensed and administered, confirmed by NDC.

How Pabau simplifies HCPCS code J7322 billing workflows

No competing reference page for J7322 connects the billing workflow to what actually happens in a practice management system. That gap creates problems: billers manually transfer J-code details from paper logs to claims, NDC numbers get transcribed incorrectly, and drug inventory records sit outside the billing system.

Pabau’s claims management software and injectable drug inventory tracking bring the buy-and-bill workflow into a single system. When a clinician administers Hymovis, the drug record updates automatically and the J-code populates on the claim with the correct unit count. NDC numbers recorded at the point of dispensing carry through to the CMS-1500 without manual re-entry.

• Inventory management: Track Hymovis vials by lot number and expiration date. Pabau flags low stock and expiring inventory before it becomes a billing problem.
• Automated J-code population: Pre-configured drug records link Hymovis to J7322 with 8 units per vial, eliminating the per-claim unit calculation that trips up manual billing.
• NDC capture at dispensing: Record the NDC at the point of administration; it flows directly into the claim rather than requiring a separate lookup.
• Claim validation: Built-in checks flag missing diagnosis codes and unit mismatches before the claim leaves the practice, reducing first-pass denial rates.

For practices managing denial management workflows across multiple in-office drug programs, centralizing inventory, administration records, and claim preparation in one platform closes the most common error pathways.

Conclusion

Billing HCPCS code J7322 correctly comes down to three details: the right unit count (8 units per 8 mg vial), the right ICD-10 pairing (M17 series with laterality), and the right documentation trail (conservative therapy failure on record before the first injection). Miss any one of them and you’re looking at a denial or a post-payment audit.

Pabau’s inventory and claims management tools connect drug dispensing records directly to claim preparation, so J7322 billing units, NDC numbers, and diagnosis codes move from the clinical record to the CMS-1500 without manual re-entry. To see how practices running in-office viscosupplementation programs use Pabau, explore the claims management feature or speak with the team.

Continue your research

Need to understand the full claim submission process? What is medical billing covers the end-to-end claim lifecycle for physician-administered drugs and services.

Getting ERA remittances back with denial codes on J7322? Denial management in healthcare explains how to read remark codes and build an appeals workflow.

Want to understand how your revenue cycle connects to ASP-based reimbursement? What is revenue cycle management maps the full cycle from charge capture to payment posting.

Frequently Asked Questions